骨髓干细胞治疗部分改善表达突变型人α1-抗胰蛋白酶小鼠肝脏的病理后果
研究在表达人α1-抗胰蛋白酶Z变体(AATZ)的转基因小鼠中,移植小鼠骨髓祖细胞或人间充质干细胞(MSCs),观察到含球状包涵体肝细胞减少、肝炎症、纤维化和肝细胞凋亡部分改善,肝糖原储存及血清葡萄糖水平改善。作者认为骨髓干细胞移植可能是AATD相关肝病有前景的疗法。
要点
- 小鼠骨髓祖细胞和人间充质干细胞分别替代约40%和13%宿主肝细胞。
- 移植后含球状包涵体肝细胞减少,无包涵体肝细胞增殖改善,肝炎症、纤维化和肝细胞凋亡部分改善。
- 细胞治疗还改善表达人AATZ小鼠的肝糖原储存和血清葡萄糖水平。
核心结论
- 作者认为骨髓干细胞移植可能是AATD相关肝病有前景的疗法。
研究设计与样本
- 在表达人α1-抗胰蛋白酶Z变体(AATZ)的转基因小鼠中进行的细胞移植研究,移植小鼠骨髓祖细胞和人间充质干细胞(MSCs)。
主要发现
- 小鼠骨髓祖细胞和人间充质干细胞分别替代约40%和13%宿主肝细胞。
- 移植后含球状包涵体肝细胞减少,宿主来源无包涵体肝细胞及供体来源细胞增殖改善。
- 移植部分改善肝病理,表现为炎症反应、纤维化和肝细胞凋亡改善。
- 细胞治疗改善表达人AATZ小鼠的肝糖原储存和血清葡萄糖水平。
- 初步结果显示移植人骨髓来源MSCs后含球状包涵体肝细胞减少,供体来源细胞表达人AAT蛋白。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disease, caused by mutation of the AAT gene. Accumulation of mutated AAT protein aggregates in hepatocytes leads to endoplasmic reticulum stress, resulting in impairment of liver functions and, in some cases, hepatocellular carcinoma, whereas decline of AAT levels in sera is responsible for pulmonary emphysema. In advanced liver disease, the only option for treatment is liver transplantation, whereas AAT replacement therapy is therapeutic for emphysema. Given that hepatocytes are the primary affected cells in AATD, we investigated whether transplantation of bone marrow (BM)-derived stem cells in transgenic mice expressing human AATZ (the Z variant of AAT) confers any competitive advantages compared to host cells that could lead to pathological improvement. Mouse BM progenitors and human mesenchymal stem cells (MSCs) appeared to contribute in replacement of 40% and 13% host hepatocytes, respectively. Transplantation of cells resulted in decline of globule-containing hepatocytes, improvement in proliferation of globule-devoid hepatocytes from the host-derived hepatocytes, and apparently, donor-derived cells. Further analyses revealed that transplantation partially improves liver pathology as reflected by inflammatory response, fibrosis, and apoptotic death of hepatocytes. Cell therapy was also found to improve liver glycogen storage and sera glucose level in mice expressing human AATZ mice. These overall improvements in liver pathology were not restricted to transplantation of mouse BM cells. Preliminary results also showed that following transplantation of human BM-derived MSCs, globule-containing hepatocytes declined and donor-derived cells expressed human AAT protein. CONCLUSION: These results suggest that BM stem cell transplantation may be a promising therapy for AATD-related liver disease. (Hepatology 2017;65:1319-1335).
引用
- Baligar P, Kochat V, Arindkar SK, et al. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin. Hepatology. 2017. PMID: 28056498. doi:10.1002/hep.29027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。